Nature Communications (May 2022)
p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis
- Laura Solé,
- Teresa Lobo-Jarne,
- Daniel Álvarez-Villanueva,
- Josune Alonso-Marañón,
- Yolanda Guillén,
- Marta Guix,
- Irene Sangrador,
- Catalina Rozalén,
- Anna Vert,
- Antonio Barbachano,
- Joan Lop,
- Marta Salido,
- Beatriz Bellosillo,
- Raquel García-Romero,
- Marta Garrido,
- Jessica González,
- María Martínez-Iniesta,
- Erika López-Arribillaga,
- Ramón Salazar,
- Clara Montagut,
- Ferrán Torres,
- Mar Iglesias,
- Toni Celià-Terrassa,
- Alberto Muñoz,
- Alberto Villanueva,
- Anna Bigas,
- Lluís Espinosa
Affiliations
- Laura Solé
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- Teresa Lobo-Jarne
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- Daniel Álvarez-Villanueva
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- Josune Alonso-Marañón
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- Yolanda Guillén
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- Marta Guix
- Department of Oncology, Institut Mar d’Investigacions Mèdiques, CIBERONC, Universitat Pompeu Fabra
- Irene Sangrador
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- Catalina Rozalén
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- Anna Vert
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- Antonio Barbachano
- CIBERONC, Instituto de Salud Carlos III
- Joan Lop
- Department of Pathology, Institut Mar d’Investigacions Mèdiques, Universitat Autònoma de Barcelona
- Marta Salido
- Department of Pathology, Institut Mar d’Investigacions Mèdiques, Universitat Autònoma de Barcelona
- Beatriz Bellosillo
- CIBERONC, Instituto de Salud Carlos III
- Raquel García-Romero
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- Marta Garrido
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- Jessica González
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- María Martínez-Iniesta
- Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet del Llobregat
- Erika López-Arribillaga
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- Ramón Salazar
- CIBERONC, Instituto de Salud Carlos III
- Clara Montagut
- CIBERONC, Instituto de Salud Carlos III
- Ferrán Torres
- Biostatistics Unit, Medical School, Universitat Autònoma de Barcelona
- Mar Iglesias
- CIBERONC, Instituto de Salud Carlos III
- Toni Celià-Terrassa
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- Alberto Muñoz
- CIBERONC, Instituto de Salud Carlos III
- Alberto Villanueva
- Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet del Llobregat
- Anna Bigas
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- Lluís Espinosa
- Cancer Research Program, Institut Mar d’Investigacions Mèdiques, CIBERONC, Hospital del Mar
- DOI
- https://doi.org/10.1038/s41467-022-30382-9
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
The failure of chemotherapy in colorectal cancer is currently unclear. Here, the authors show that upon sub-lethal dose of chemotherapy wild-type p53 colorectal cancers acquire a quiescence-like phenotype and a YAP-dependent fetal-like intestinal stem cell state associated with a higher metastatic activity and poor prognosis in patients.
